Taken together, our present results demonstrate that such compounds can serve as a promising candidate for the treatment of AD and establish a rational foundation for future design of new pharmacological agents as multi-target inhibitors of AChE, BChE, and Aβ aggregation. This evidence concerns the gene BCHE and Alzheimer disease.